GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease

Yazhou Li, Kara B. Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A. Bailey, Harold W. Holloway, David Tweedie, Tracyann Perry, Mark P. Mattson, Dimitrios Kapogiannis, Kumar Sambamurti, Debomoy K. Lahiri, Nigel H. Greig

Research output: Contribution to journalArticlepeer-review

204 Scopus citations

Abstract

Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-β protein (Aβ) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Aβ and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Aβ protein precursor and Aβ, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.

Original languageEnglish (US)
Pages (from-to)1205-1219
Number of pages15
JournalJournal of Alzheimer's Disease
Volume19
Issue number4
DOIs
StatePublished - 2010

Keywords

  • 3xTg-AD mice
  • Alzheimer's disease
  • Amyloid-β peptide
  • Amyloid-β protein precursor
  • Dementia
  • Diabetes
  • Extendin-4
  • Glucagon-like peptide-1
  • Neuroprotection
  • Streptozocin
  • Tau

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Fingerprint Dive into the research topics of 'GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this